ANPARIO PLC (ANP) — Final Results for the twelve months to 31 December 2025

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to the ANPARIO PLC investor presentation. Questions are encouraged and can be submitted via the Q and A tab situated on the right hand side of your screen. Before we begin, I'd like to submit the following poll, which I kindly ask you to submit your responses to. I'd now like to hand over to CEO Richard Edwards. Richard, good afternoon. Yes. Thank you, Jack. Welcome everyone to ANPARIO's final results for financial year 2025. Mark is with me, the the chief financial officer, Mark Wilson. And what we'll start with is just run through the numbers and then look at some of the what's happening along the lines in some of the regions that we operate in. And, obviously, particularly with The Middle East, we already have some questions on that, but we'll probably answer those as we go through the geographic spread. So, Mark, if you'd like to start with with the numbers, we'll take questions at the end. So just if you can put those through this through the system, then we'll answer, hopefully, all of them at the by the end. Mark, over to you. Okay. Thank you, Richard. Right. Just moving on. Just take you through the quick highlights. I'm sure you've seen these since we've announced the results, but another fantastic year of progress at ANPARIO, including the first full year contribution from BioVet in terms of the key sort of financial metrics. Then we had revenue up 24%, even higher growth in gross profit of 34%, thanks to further improvement in gross margins. Adjusted EBITDA up slightly higher than that as well, 38%, taking us to a record 9,600,000. Cash growth again despite having some outflows relation related to final payments for the BioVac acquisition, so good cash generation again. And that diluted adjusted earnings per share of 33% and an ...